Novai, a biotechnology start-up originating from University College London, has secured £500,000 in seed funding in a round led by SFC Capital.
The funding will be used to further develop Novai’s AI-powered technology that enables medical imaging equipment to identify eye disease at a cellular level up to 18 months earlier than current gold-standard processes. Novai has also appointed Gordon Bethwaite as acting CEO and added three new senior board members.
Novai was founded by Professor Francesca Cordeiro from UCL and Imperial College London. When applied to images taken using the DARC (Detection of Apoptosing Retinal Cell) technique developed by Professor Cordeiro, Novai’s AI algorithm is able to predict progressive glaucomatous damage 18 months before current gold standard OCT retinal imaging technology.
Novai’s technology has been approved as an exploratory biomarker for use in studies of glaucoma and AMD (age-related macular degeneration). The team is also researching its potential for application in neurodegenerative conditions, such as multiple sclerosis, Alzheimer’s, and Parkinson’s Disease.
Novai recently closed its first commercial agreement, a research collaboration with Santen USA, and is also actively responding to significant global commercial interest.
Rohallah Ghasemi, investment manager at SFC Capital, said: “Novai’s innovative combination of technology and biomedicine represents the future of preventative care, with the potential to make a massive difference for anyone who might suffer from degenerative diseases in the future. The founders have assembled an extraordinary team of experts and advisors, and we are pleased to be supporting them as they continue to prove the capabilities of the technology and grow the company. We’re excited to see what they achieve next.”
Following the closing of seed funding, Novai recently appointed Gordon Bethwaite as acting CEO.
Speaking about his appointment, Bethwaite said: "Througout my career, I’ve worked with gold-standard eyecare companies and products, and have seen first-hand the positive impact that ground-breaking technology can have on patients’ lives. DARC has the potential to become one of those technologies, and I’m excited to be part of this amazing team bringing it to market. Playing a role in the development of new treatments and standards of care for patients suffering with degenerative sight loss is what motivates us to success with DARC.”
Novai has also added Dr. Karl Keegan, Rob Thornhill, and Dr. Berwyn Clarke to its board, with Dr. Clarke joining as chairman. Dr. Clarke has over 30 years’ experience in the pharmaceutical and diagnostics industries, and is a specialist in personalised medicine, companion diagnostics, and the development and commercialisation of novel diagnostics. Dr. Keegan and Mr. Thornhill bring experience of business development and big pharma.
